港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议

智通财经2025-12-17

智通财经APP获悉，旺山旺水-B(02630)午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。根据该协议，先声药业将获得氢溴酸氘瑞米德韦干混悬剂在大中华区用于抗呼吸道合胞病毒（RSV）感染以及抗人偏肺病毒（HMPV）感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592663449?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-17 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592663449","market":"fut","top_or_hot":-1,"title":"港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，旺山旺水-B(02630)午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。根据该协议，先声药业将获得氢溴酸氘瑞米德韦干混悬剂在大中华区用于抗呼吸道合胞病毒（RSV）感染以及抗人偏肺病毒（HMPV）感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1382480.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 旺山旺水-B(02630)午后拉升逾15% 近期与先声药业就VV116新适应症订立许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 13:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1382480.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，旺山旺水-B(02630)午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。根据该协议，先声药业将获得氢溴酸氘瑞米德韦干混悬剂在大中华区用于抗呼吸道合胞病毒（RSV）感染以及抗人偏肺病毒（HMPV）感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1382480.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1382480.html","article_id":"2592663449","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592663449","pubTimestamp":1765949937,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，旺山旺水-B午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。旺山旺水与先声药业强强联合，发挥各自研发、生产及商业化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。公开资料显示，旺山旺水重点布局神经精神、生殖健康和病毒感染三大治疗领域。目前，旺山旺水的两款核心产品分别是LV232和TPN171。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","02096":"先声药业","02630":"旺山旺水-B"},"translate_title":"Changes in Hong Kong stocks | Wangshan Wangshui-B (02630) rose more than 15% in the afternoon and recently entered into a licensing agreement with Simcere Pharmaceuticals for the new indication of VV116","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1.5,"02630":1.5},"content_text":"智通财经APP获悉，旺山旺水-B(02630)午后拉升逾15%，截至发稿，涨14.81%，报88港元，成交额1333.12万港元。消息面上，旺山旺水本月初发布公告，与先声药业就VV116新适应症订立许可协议。根据该协议，先声药业将获得氢溴酸氘瑞米德韦干混悬剂在大中华区用于抗呼吸道合胞病毒（RSV）感染以及抗人偏肺病毒（HMPV）感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研发、生产及商业化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。公开资料显示，旺山旺水重点布局神经精神、生殖健康和病毒感染三大治疗领域。截至2025年10月21日，公司已搭建多元化的9个创新管线，其中2个处于商业化阶段，4个处于临床阶段，3个处于临床前阶段。除了创新药管线，公司还布局仿制药板块，其中3款药物处于商业化或接近商业化阶段。目前，旺山旺水的两款核心产品分别是LV232和TPN171。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592663449","isCrawlerRequest":true}